Mécanisme d’activation de l’oncogène BRAF - L’union fait la force

Hugo Lavoie; Marc Therrien

doi:doi:10.1051/medsci/2010265459

Accès gratuit

Numéro		Med Sci (Paris) Volume 26, Numéro 5, Mai 2010


Page(s)		459 - 460
Section		Nouvelles
DOI		http://dx.doi.org/10.1051/medsci/2010265459
Publié en ligne		15 May 2010

Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283 : 125–34.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 : 949–54.
Ashton-Beaucage D, Therrien M. La signalisation RTK/RAS/ERK élargie : contributions de la génétique à l’assemblage d’un réseau de signalisation. Med Sci (Paris) 2010; 26 (sous presse).
Claperon A, Therrien M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 2007; 26 : 3143–58.
Roy F, Laberge G, Douziech M, et al. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev 2002; 16 : 427–38.
Rajakulendran T, Sahmi M, Lefrancois M, et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009; 461 : 542–5.
Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116 : 855–67.
Fenton AW. Allostery: an illustrated definition for the second secret of life. Trends Biochem Sci 2008; 33 : 420–5.
Dar AC, Dever TE, Sicheri F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005; 122 : 887–900.
Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125 : 1137–49.
Zeqiraj E, Filippi BM, Deak M, et al. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009; 326 : 1707–11.

[1] Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283 : 125–34.

[2] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 : 949–54.

[3] Ashton-Beaucage D, Therrien M. La signalisation RTK/RAS/ERK élargie : contributions de la génétique à l’assemblage d’un réseau de signalisation. Med Sci (Paris) 2010; 26 (sous presse).

[4] Claperon A, Therrien M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 2007; 26 : 3143–58.

[5] Roy F, Laberge G, Douziech M, et al. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev 2002; 16 : 427–38.

[6] Rajakulendran T, Sahmi M, Lefrancois M, et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009; 461 : 542–5.

[7] Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116 : 855–67.

[8] Fenton AW. Allostery: an illustrated definition for the second secret of life. Trends Biochem Sci 2008; 33 : 420–5.

[9] Dar AC, Dever TE, Sicheri F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005; 122 : 887–900.

[10] Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125 : 1137–49.

[11] Zeqiraj E, Filippi BM, Deak M, et al. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009; 326 : 1707–11.

Prix Nobel 2012